Navigation Links
Pharmaxis to Apply to Market Bronchitol in Australia
Date:2/13/2008

SYDNEY, Australia, Feb. 14 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it will apply for Australian marketing approval of Bronchitol for patients with bronchiectasis, following a meeting with the Australian Therapeutic Goods Administration (TGA).

Bronchitol is being developed as a twice daily therapy for people with the incurable lung condition Bronchiectasis. The meeting with the TGA on 12 February was arranged following the successful completion of a Phase III clinical study of Bronchitol in the second half of 2007. The trial demonstrated a significant improvement in the quality of life for patients treated with Bronchitol, and a significant difference in their mucus clearance.

Pharmaxis will submit its marketing authorisation application following the conclusion of the ongoing safety component of the Phase III trial - an optional 12 month extension to determine the safety of long-term Bronchitol treatment. This component of the trial has had a high participation rate and a low withdrawal rate, and will complete mid-year. Pharmaxis will file the marketing application during the third quarter of 2008.

"We are delighted that our discussions with the TGA have provided a path forward for bringing Bronchitol to market in Australia," said Pharmaxis Chief Executive Officer Alan Robertson.

"More than 20,000 Australians suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for this patient group in over 20 years -- addressing an important medical need."

Bronchiectasis is an incurable, degenerative and chronic lung condition that makes breathing difficult through excessive mucus build up in the lungs. Pharmaxis has the only product in Phase III clinical trials for bronchiectasis anywhere in the world.

Over 600,000 patients worldwide suffer from bronchiectasis. Total U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the disorder; and an increased overall cost of US$630 million. Widespread availability of high resolution scanners is leading to increasing diagnosis and the understanding that bronchiectasis is more common than previously thought. Pharmaxis is developing Bronchitol as a daily treatment administered by inhalation to the patient's lungs.

To find out more about Pharmaxis go to http://www.pharmaxis.com.au .

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson -- Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

Australia:

Virginia Nicholls,

Tel: +61-417-610-824

Email: virginia.nicholls@pharmaxis.com.au

United States:

Brandon Lewis, Trout Group,

Tel: +1-646-378-2915

Email: blewis@troutgroup.com


'/>"/>
SOURCE Pharmaxis
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Phase III Trial Finds Pharmaxis Bronchitol Effective
2. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
3. Pharmaxis Closes Share Purchase Plan
4. Pharmaxis Appoints Portuguese Distributor for Aridol
5. Pharmaxis Aridol Gains First Asian Approval
6. Pharmaxis Investor Conference Call
7. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
8. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
9. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
10. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
11. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... York, NY (PRWEB) , ... May 04, 2016 , ... ... (NF), a genetic disorder that causes tumors to grow on nerves throughout the body. ... or cure. , Through numerous community events held during the month of May, as ...
(Date:5/4/2016)... According to a new market ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... expand at a CAGR of 17.1% from 2016 to ... Metabolomics is the extensive study of small molecules, ... organisms. Together, these small molecules and their interactions in ...
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to announce ... , Doug began his career at PBI-Gordon in February 1988, after finishing his masters ... of roles, ranging from customer service to national product manager, to helping develop, name ...
(Date:5/4/2016)... ... 04, 2016 , ... Nutrafol®, a first-to-market smart-supplement for healthy ... stress related hair loss. With patent-pending formulas for both female hair loss and ... the medical and salon channels nationwide. , Dermatologists, Plastic Surgeons and hair ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):